Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Associations between the APOE-ε2 and APOE-ε4 alleles with resistance and resilience against Alzheimer's disease pathology

Ossenkoppele, Rik LU and Groot, Colin LU (2021) In Alzheimer's & dementia : the journal of the Alzheimer's Association 17.
Abstract

BACKGROUND: To examine associations between the APOE-ε2 and APOE-ε4 alleles and core Alzheimer's disease (AD) pathological hallmarks as measured by amyloid-β (Aβ) and tau PET in older individuals without dementia. METHOD: We analyzed data from 462 ADNI participants without dementia who underwent Aβ ([18 F]florbetapir or [18 F]florbetaben) and tau ([18 F]flortaucipir) PET, structural MRI and cognitive testing. Employing APOE-ε3 homozygotes as the reference group, associations between APOE-ε2 and APOE-ε4 carriership with global Aβ PET and regional tau PET measures (entorhinal cortex [ERC], inferior temporal cortex, and Braak-V/VI neocortical composite regions) were investigated using linear regression models. In a subset of 156... (More)

BACKGROUND: To examine associations between the APOE-ε2 and APOE-ε4 alleles and core Alzheimer's disease (AD) pathological hallmarks as measured by amyloid-β (Aβ) and tau PET in older individuals without dementia. METHOD: We analyzed data from 462 ADNI participants without dementia who underwent Aβ ([18 F]florbetapir or [18 F]florbetaben) and tau ([18 F]flortaucipir) PET, structural MRI and cognitive testing. Employing APOE-ε3 homozygotes as the reference group, associations between APOE-ε2 and APOE-ε4 carriership with global Aβ PET and regional tau PET measures (entorhinal cortex [ERC], inferior temporal cortex, and Braak-V/VI neocortical composite regions) were investigated using linear regression models. In a subset of 156 participants, we also investigated associations between APOE genotypeand regional tau accumulation over time using linear mixed models. Finally, we assessed whether Aβ mediated the cross-sectional and longitudinal associations between APOE genotype and tau. RESULT: Compared to APOE-ε3 homozygotes, APOE-ε2 carriers had lower global Aβ burden (βstd [95% confidence interval (CI)]:-0.31[-0.45,-0.16], p=0.034), but did not differ on regional tau burden (Figure-1) or tau accumulation over time (Figure-2). APOE-ε4 participants showed higher Aβ (βstd [95%CI]: 0.64[0.42,0.82], p<0.001) and tau burden (βstd range: 0.27-0.51, all p<0.006). In mediation analyses, APOE-ε4 only retained an Aβ-independent effect on tau in the ERC. APOE-ε4showed a trend towards increased tau accumulation over time in Braak-V/VI compared to APOE-ε3 homozygotes (βstd [95%CI]: 0.10[-0.02,0.18], p=0.11), and this association was fully mediated by baseline Aβ (Figure-3). CONCLUSION: Our data suggest that the established protective effect of the APOE-ε2 allele against developing clinical AD is primarily linked to resistance against Aβ deposition rather than tau pathology.

(Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Alzheimer's & dementia : the journal of the Alzheimer's Association
volume
17
article number
e051346
publisher
Wiley
external identifiers
  • pmid:35108977
  • scopus:85123973395
ISSN
1552-5279
DOI
10.1002/alz.051346
language
English
LU publication?
yes
id
fba1b611-23c1-433c-8ee5-d15f565fab5c
date added to LUP
2022-04-05 15:28:32
date last changed
2022-04-05 17:00:45
@article{fba1b611-23c1-433c-8ee5-d15f565fab5c,
  abstract     = {{<p>BACKGROUND: To examine associations between the APOE-ε2 and APOE-ε4 alleles and core Alzheimer's disease (AD) pathological hallmarks as measured by amyloid-β (Aβ) and tau PET in older individuals without dementia. METHOD: We analyzed data from 462 ADNI participants without dementia who underwent Aβ ([18 F]florbetapir or [18 F]florbetaben) and tau ([18 F]flortaucipir) PET, structural MRI and cognitive testing. Employing APOE-ε3 homozygotes as the reference group, associations between APOE-ε2 and APOE-ε4 carriership with global Aβ PET and regional tau PET measures (entorhinal cortex [ERC], inferior temporal cortex, and Braak-V/VI neocortical composite regions) were investigated using linear regression models. In a subset of 156 participants, we also investigated associations between APOE genotypeand regional tau accumulation over time using linear mixed models. Finally, we assessed whether Aβ mediated the cross-sectional and longitudinal associations between APOE genotype and tau. RESULT: Compared to APOE-ε3 homozygotes, APOE-ε2 carriers had lower global Aβ burden (βstd [95% confidence interval (CI)]:-0.31[-0.45,-0.16], p=0.034), but did not differ on regional tau burden (Figure-1) or tau accumulation over time (Figure-2). APOE-ε4 participants showed higher Aβ (βstd [95%CI]: 0.64[0.42,0.82], p&lt;0.001) and tau burden (βstd range: 0.27-0.51, all p&lt;0.006). In mediation analyses, APOE-ε4 only retained an Aβ-independent effect on tau in the ERC. APOE-ε4showed a trend towards increased tau accumulation over time in Braak-V/VI compared to APOE-ε3 homozygotes (βstd [95%CI]: 0.10[-0.02,0.18], p=0.11), and this association was fully mediated by baseline Aβ (Figure-3). CONCLUSION: Our data suggest that the established protective effect of the APOE-ε2 allele against developing clinical AD is primarily linked to resistance against Aβ deposition rather than tau pathology.</p>}},
  author       = {{Ossenkoppele, Rik and Groot, Colin}},
  issn         = {{1552-5279}},
  language     = {{eng}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's & dementia : the journal of the Alzheimer's Association}},
  title        = {{Associations between the APOE-ε2 and APOE-ε4 alleles with resistance and resilience against Alzheimer's disease pathology}},
  url          = {{http://dx.doi.org/10.1002/alz.051346}},
  doi          = {{10.1002/alz.051346}},
  volume       = {{17}},
  year         = {{2021}},
}